Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G. Pal R, et al. Among authors: tartaglia j. J Virol. 2002 Jan;76(1):292-302. doi: 10.1128/jvi.76.1.292-302.2002. J Virol. 2002. PMID: 11739694 Free PMC article.
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Stevceva L, Alvarez X, Lackner AA, Tryniszewska E, Kelsall B, Nacsa J, Tartaglia J, Strober W, Franchini G. Stevceva L, et al. Among authors: tartaglia j. J Virol. 2002 Nov;76(22):11659-76. doi: 10.1128/jvi.76.22.11659-11676.2002. J Virol. 2002. PMID: 12388726 Free PMC article.
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G. Pal R, et al. Among authors: tartaglia j. J Virol. 2006 Apr;80(8):3732-42. doi: 10.1128/JVI.80.8.3732-3742.2006. J Virol. 2006. PMID: 16571790 Free PMC article.
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
Silva de Castro I, Gordon SN, Liu J, Bissa M, McKinnon K, Trinh HV, Doster MN, Schifanella L, Liyanage NP, Cao J, Cheng O, Foulds K, Roederer M, Koup RA, Shen X, Tomaras GD, Venzon DJ, Forthal DN, Fouts T, Montefiori DC, Tartaglia J, Rao M, Ostrowski M, Franchini G, Vaccari M. Silva de Castro I, et al. Among authors: tartaglia j. J Virol. 2020 Feb 28;94(6):e01933-19. doi: 10.1128/JVI.01933-19. Print 2020 Feb 28. J Virol. 2020. PMID: 31896599 Free PMC article.
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G. Benson J, et al. Among authors: tartaglia j. J Virol. 1998 May;72(5):4170-82. doi: 10.1128/JVI.72.5.4170-4182.1998. J Virol. 1998. PMID: 9557706 Free PMC article.
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G. Pegu P, et al. Among authors: tartaglia j. J Virol. 2013 Feb;87(3):1708-19. doi: 10.1128/JVI.02544-12. Epub 2012 Nov 21. J Virol. 2013. PMID: 23175374 Free PMC article.
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.
Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G. Vaccari M, et al. Among authors: tartaglia j. J Virol. 2013 Mar;87(6):3538-48. doi: 10.1128/JVI.02863-12. Epub 2013 Jan 16. J Virol. 2013. PMID: 23325681 Free PMC article.
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R. Asbach B, et al. Among authors: tartaglia j. J Virol. 2016 Mar 28;90(8):4133-4149. doi: 10.1128/JVI.03135-15. Print 2016 Apr. J Virol. 2016. PMID: 26865719 Free PMC article.
193 results